Vitality Watch

Dossier clinicaltrials trial early 19-aug-2026
Small or early-phase human trial or pilot study

MItochondrial Intervention for Resilience in Older Adults With Coenzyme Q10

Key claim: A randomized, double-blind, placebo-controlled trial will test whether 200 mg daily CoQ10 for 10 weeks improves mitochondrial resilience, chronic inflammation, metabolic health, physical and cognitive function, and prefrailty features in community-dwelling adults aged 65+.

Abstract

This randomized, double-blind, placebo-controlled clinical trial will investigate whether 10 weeks of CoQ10 supplementation can improve biological resilience and functional health in community-dwelling adults aged 65 years or older with signs of reduced biological resilience or prefrailty.

Participants will be randomly assigned in a 1:1 ratio to receive either 200 mg of CoQ10 daily or matching placebo for 10 weeks. The study will assess the effects of CoQ10 supplementation on mitochondrial functional resilience, chronic low-grade inflammation, metabolic health, physical performance, cognitive function, and objective measures of skin aging.

The study will also investigate whether baseline biological and functional characteristics can identify individuals who are more likely to benefit from CoQ10 supplementation. An exploratory aim is to develop a multidimensional composite index of biological resilience integrating molecular, biochemical, functional, and clinical measures of aging.

The study will provide evidence on whether a mitochondria-targeted intervention with CoQ10 may represent a potential strategy for improving functional resilience and reducing features of prefrailty in older adults.

Why this matters

A randomized, double-blind, placebo-controlled trial will test whether 200 mg daily CoQ10 for 10 weeks improves mitochondrial resilience, chronic inflammation, metabolic health, physical and cognitive function, and prefrailty features in community-dwelling adults aged 65+.

Source

Link

Briefing card

MItochondrial Intervention for Resilience in Older Adults With Coenzyme Q10
Stage: trial early · clinicaltrials · 19-aug-2026

A randomized, double-blind, placebo-controlled trial will test whether 200 mg daily CoQ10 for 10 weeks improves mitochondrial resilience, chronic inflammation, metabolic health, physical and cognitive function, and prefrailty features in community-dwelling adults aged 65+.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07772336

build build 880 · 2bcef25 · 2026-11-18